Meyers, FH; Rose, AJ; Smith, DE. Incidents involving the Haight-Ashbury population and some uncommonly used drugs J. Psychedelic Drugs, 1 Apr 1968, 1 (2), 139–146. 842 kB. https://doi.org/10.1080/02791072.1968.10524531
Clarke, EGC. The identification of some proscribed psychedelic drugs J. Forensic Sci. Soc., 1 Jan 1967, 7 (1), 46-50. 336 kB. https://doi.org/10.1016/S0015-7368(67)70370-9 TLC
Helm, K. Synthese und funktionelle In-vitro-Pharmakologie neuer Liganden des 5-HT2A-Rezeptors aus der Klasse Ph. D. Thesis, Universität Regensburg, Dresden, 1 Jan 2014. 3.2 MB. #34 LC,MS,NMR,IR
Jakubczyk, D; Cheng, JZ; O'Connor, SE. Biosynthesis of the ergot alkaloids Nat. Prod. Rep., 28 Aug 2014, 31 (10), 1328-1338. 476 kB. https://doi.org/10.1039/C4NP00062E
Friedman, AP. Clinical observations with 1-methyl-lysergic acid butanolamide (UML-491) in vascular headache Angiology, 1 Aug 1960, 11 (4), 364–366. 259 kB. https://doi.org/10.1177/000331976001100409 #UML-491
Jacob, P; Shulgin, AT. Structure-activity relationships of the classic hallucinogens and their analogs In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 74–91. 51 kB.
Shulgin, AT. Basic Pharmacology and Effects In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 24 Apr 2003; pp 67–137. 6.3 MB.
Shulgin, AT. Chemistry of psychotomimetics In Handbook of Experimental Pharmacology. Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs; Hoffmeister, F; Stille, G, Eds., Springer-Verlag, Berlin, 1 Jan 1982; Vol. 55 (3), pp 3–29. 928 kB. https://doi.org/10.1007/978-3-642-67770-0_1 #8l
Shulgin, AT. Psychotomimetic agents In Psychopharmacological Agents; Gordon, M, Ed., Academic Press, New York, 1 Jan 1976; Vol. 4, pp 59–146. 3.1 MB. #V
Nichols, DE. Potential psychotomimetics: Bromomethoxyamphetamines and structural congeners of lysergic acid Ph. D. Thesis, University of Iowa, Iowa City, IA, 1 May 1973. 13.0 MB. #5 NMR,IR,other
Heim, R. Synthesis and pharmacology of potent 5-HT2A receptor agonists with N-2-methoxybenzyl partial structure SC. D. Thesis, Freie Universität, Berlin, 1 Jan 2004. 3.9 MB. #27 In German. MS,NMR,IR
Pertz, HH; Brown, AM; Gager, TL; Kaumann, AJ. Simple O-acylated derivatives of lysergol and dihydrolysergol-I: Synthesis and interaction with 5-HT2A, 5-HT2C and 5-HT1B receptors, and α1 adrenergic receptors J. Pharm. Pharmacol., 1 Mar 1999, 51 (3), 319–330. 192 kB. https://doi.org/10.1211/0022357991772321 #Methysergide MS,NMR,other
Mesley, RJ; Evans, WH. Infrared identification of lysergide (LSD) J. Pharm. Pharmacol., 1 Nov 1969, 21 (11), 713–720. 484 kB. https://doi.org/10.1111/j.2042-7158.1969.tb08160.x #Methysergide IR
Gupta, SP; Singh, P; Bindal, MC. QSAR studies on hallucinogens Chem. Rev., 1 Dec 1983, 83 (6), 633–649. 2.8 MB. https://doi.org/10.1021/cr00058a003 #3d
Klein, MT; Dukat, M; Glennon, RA; Teitler, M. Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: A comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships J. Pharmacol. Exp. Ther., 1 Jun 2011, 337 (3), 860–867. 1.7 MB. https://doi.org/10.1124/jpet.111.179606 #43